Share Price and Basic Stock Data
Last Updated: December 23, 2025, 8:35 am
| PEG Ratio | 0.14 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Lupin Ltd operates in the fiercely competitive pharmaceuticals sector, where it has shown resilience and adaptability. In the fiscal year ending March 2025, the company reported a remarkable revenue of ₹22,708 Cr, up from ₹20,011 Cr in FY 2024. This upward trajectory reflects a robust sales growth trend, with quarterly sales consistently rising from ₹4,814 Cr in June 2023 to a projected ₹6,268 Cr by June 2025. Such growth indicates not only effective product positioning but also the ability to navigate market challenges. The company’s expansion into new therapeutic areas and geographies seems to be paying off, as evidenced by its improved performance metrics. However, it is crucial to consider that the pharmaceutical market is subject to regulatory scrutiny and price controls, which could impact revenue generation in the long term. Overall, the revenue trends suggest that Lupin is on a solid path, though it must remain vigilant against potential industry headwinds.
Profitability and Efficiency Metrics
Lupin’s profitability appears strong, with a reported net profit of ₹3,722 Cr for the trailing twelve months. This figure reflects a significant recovery from previous years, particularly after the lows seen in FY 2022, where the company posted a net loss of ₹1,528 Cr. The operating profit margin has improved markedly, standing at 23% for FY 2025, up from just 1% in FY 2022. Such a turnaround can largely be attributed to efficient cost management and a focus on high-margin products. Furthermore, the company recorded a return on equity (ROE) of 20.6%, which suggests that it is efficiently utilizing shareholders’ funds to generate profits. However, the cash conversion cycle (CCC) of 223 days raises some concerns about liquidity management. While the company is improving its operational metrics, the efficiency of converting sales into cash remains an area that warrants close attention.
Balance Sheet Strength and Financial Ratios
Lupin’s balance sheet reflects a mix of strengths and vulnerabilities. The company reported reserves of ₹19,541 Cr, which provides a solid buffer against market fluctuations. However, its total borrowings stood at ₹6,217 Cr, indicating a debt-to-equity ratio of 0.29, suggesting a relatively conservative leverage strategy. This is supported by an impressive interest coverage ratio (ICR) of 18.58x, which implies that Lupin can comfortably meet its interest obligations. Moreover, the current ratio of 1.87x indicates a healthy liquidity position, ensuring that the company can cover its short-term liabilities. Nonetheless, the price-to-book value ratio of 5.38x suggests that the stock may be trading at a premium, which could deter value-oriented investors. Overall, while the balance sheet is generally strong, the market’s perception of its valuation may introduce volatility.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Lupin Ltd reveals a diverse investor base, with promoters holding 46.89% of the shares, while foreign institutional investors (FIIs) account for 20.50% and domestic institutional investors (DIIs) hold 26.56%. This blend of ownership suggests a stable governance structure, with promoters retaining significant control and institutional investors showing confidence in the company’s prospects. Notably, the FII stake has gradually increased, rising from 13.98% in December 2022 to 20.50% by March 2025. This trend could indicate growing international confidence in Lupin’s operational strategies and market positioning. However, the decline in public shareholding from 10.39% in March 2023 to 6.06% in September 2025 may raise some red flags about retail investor sentiment. A healthy balance of institutional and retail interest is critical for maintaining stock liquidity and price stability.
Outlook, Risks, and Final Insight
Looking ahead, Lupin is positioned to leverage its strong operational metrics and market presence, but it must navigate a landscape fraught with risks. The pharmaceutical sector is known for its regulatory challenges, which could impact product approvals and pricing strategies. Additionally, rising competition, particularly from generic drug manufacturers, poses a threat to Lupin’s market share and profit margins. Another concern is the company’s cash conversion cycle, which, while improving, still indicates potential liquidity issues that could arise during periods of lower sales. For retail investors, understanding these dynamics is crucial. While the stock appears to have strong fundamentals, the valuation metrics suggest caution. Investors should weigh the potential for growth against the backdrop of market volatility and industry risks. Ultimately, Lupin’s journey will depend on its ability to innovate and adapt in a rapidly changing environment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 139 Cr. | 110 | 231/84.3 | 30.6 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,437 Cr. | 407 | 479/192 | 91.9 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.4 Cr. | 49.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 49.8 Cr. | 34.0 | 34.0/17.0 | 119 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,359.35 Cr | 1,156.91 | 53.08 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,744 | 4,146 | 4,322 | 4,430 | 4,814 | 5,039 | 5,197 | 4,961 | 5,600 | 5,673 | 5,768 | 5,667 | 6,268 |
| Expenses | 3,512 | 3,693 | 3,790 | 3,852 | 3,958 | 4,121 | 4,159 | 3,964 | 4,359 | 4,332 | 4,412 | 4,346 | 4,541 |
| Operating Profit | 232 | 453 | 533 | 578 | 856 | 918 | 1,038 | 997 | 1,241 | 1,340 | 1,356 | 1,321 | 1,727 |
| OPM % | 6% | 11% | 12% | 13% | 18% | 18% | 20% | 20% | 22% | 24% | 24% | 23% | 28% |
| Other Income | 6 | 15 | 18 | 37 | 23 | 40 | 29 | 29 | 68 | 42 | 54 | 57 | 79 |
| Interest | 43 | 55 | 84 | 93 | 86 | 81 | 74 | 71 | 68 | 71 | 67 | 89 | 92 |
| Depreciation | 193 | 203 | 220 | 264 | 235 | 248 | 257 | 457 | 248 | 257 | 271 | 393 | 299 |
| Profit before tax | 2 | 210 | 246 | 258 | 559 | 630 | 736 | 498 | 993 | 1,055 | 1,071 | 896 | 1,416 |
| Tax % | 3,925% | 36% | 36% | 6% | 19% | 21% | 16% | 26% | 19% | 19% | 20% | 13% | 14% |
| Net Profit | -87 | 134 | 158 | 242 | 453 | 495 | 619 | 368 | 806 | 859 | 859 | 782 | 1,221 |
| EPS in Rs | -1.96 | 2.85 | 3.37 | 5.19 | 9.94 | 10.76 | 13.47 | 7.89 | 17.58 | 18.69 | 18.74 | 16.92 | 26.69 |
Last Updated: August 20, 2025, 7:40 am
Below is a detailed analysis of the quarterly data for Lupin Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 6,268.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,667.00 Cr. (Mar 2025) to 6,268.00 Cr., marking an increase of 601.00 Cr..
- For Expenses, as of Jun 2025, the value is 4,541.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,346.00 Cr. (Mar 2025) to 4,541.00 Cr., marking an increase of 195.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 1,727.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,321.00 Cr. (Mar 2025) to 1,727.00 Cr., marking an increase of 406.00 Cr..
- For OPM %, as of Jun 2025, the value is 28.00%. The value appears strong and on an upward trend. It has increased from 23.00% (Mar 2025) to 28.00%, marking an increase of 5.00%.
- For Other Income, as of Jun 2025, the value is 79.00 Cr.. The value appears strong and on an upward trend. It has increased from 57.00 Cr. (Mar 2025) to 79.00 Cr., marking an increase of 22.00 Cr..
- For Interest, as of Jun 2025, the value is 92.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 89.00 Cr. (Mar 2025) to 92.00 Cr., marking an increase of 3.00 Cr..
- For Depreciation, as of Jun 2025, the value is 299.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 393.00 Cr. (Mar 2025) to 299.00 Cr., marking a decrease of 94.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 1,416.00 Cr.. The value appears strong and on an upward trend. It has increased from 896.00 Cr. (Mar 2025) to 1,416.00 Cr., marking an increase of 520.00 Cr..
- For Tax %, as of Jun 2025, the value is 14.00%. The value appears to be increasing, which may not be favorable. It has increased from 13.00% (Mar 2025) to 14.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 1,221.00 Cr.. The value appears strong and on an upward trend. It has increased from 782.00 Cr. (Mar 2025) to 1,221.00 Cr., marking an increase of 439.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 26.69. The value appears strong and on an upward trend. It has increased from 16.92 (Mar 2025) to 26.69, marking an increase of 9.77.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:02 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11,286 | 12,770 | 14,256 | 17,367 | 15,797 | 14,665 | 15,375 | 15,163 | 16,405 | 16,642 | 20,011 | 22,708 | 24,751 |
| Expenses | 8,271 | 9,146 | 10,564 | 12,865 | 12,649 | 12,104 | 13,020 | 12,596 | 16,187 | 14,921 | 16,211 | 17,430 | 18,005 |
| Operating Profit | 3,015 | 3,624 | 3,691 | 4,502 | 3,148 | 2,561 | 2,355 | 2,567 | 219 | 1,721 | 3,800 | 5,278 | 6,746 |
| OPM % | 27% | 28% | 26% | 26% | 20% | 17% | 15% | 17% | 1% | 10% | 19% | 23% | 27% |
| Other Income | 105 | 235 | 184 | 106 | -1,310 | 91 | -134 | 138 | 210 | 151 | 131 | 202 | 280 |
| Interest | 27 | 10 | 59 | 153 | 204 | 302 | 363 | 141 | 143 | 274 | 312 | 295 | 355 |
| Depreciation | 261 | 435 | 487 | 912 | 1,086 | 846 | 970 | 887 | 1,659 | 881 | 1,197 | 1,169 | 1,280 |
| Profit before tax | 2,832 | 3,415 | 3,329 | 3,543 | 547 | 1,503 | 887 | 1,676 | -1,372 | 716 | 2,422 | 4,015 | 5,390 |
| Tax % | 34% | 28% | 32% | 28% | 53% | 59% | 130% | 27% | 10% | 38% | 20% | 18% | |
| Net Profit | 1,870 | 2,444 | 2,270 | 2,565 | 258 | 615 | -270 | 1,228 | -1,528 | 448 | 1,936 | 3,306 | 4,348 |
| EPS in Rs | 40.96 | 53.47 | 50.17 | 56.63 | 5.56 | 13.40 | -5.95 | 26.81 | -33.62 | 9.45 | 42.01 | 71.88 | 94.71 |
| Dividend Payout % | 15% | 14% | 15% | 13% | 90% | 37% | -101% | 24% | -12% | 42% | 19% | 17% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 30.70% | -7.12% | 13.00% | -89.94% | 138.37% | -143.90% | 554.81% | -224.43% | 129.32% | 332.14% | 70.76% |
| Change in YoY Net Profit Growth (%) | 0.00% | -37.81% | 20.12% | -102.94% | 228.31% | -282.27% | 698.72% | -779.24% | 353.75% | 202.82% | -261.38% |
Lupin Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 8% |
| 3 Years: | 11% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 55% |
| 3 Years: | 60% |
| TTM: | 63% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 15% |
| 3 Years: | 44% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 8% |
| 3 Years: | 13% |
| Last Year: | 21% |
Last Updated: September 5, 2025, 9:55 am
Balance Sheet
Last Updated: December 4, 2025, 1:35 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 91 | 91 | 91 | 91 | 91 | 91 | 91 |
| Reserves | 6,842 | 8,784 | 11,073 | 13,407 | 13,487 | 13,652 | 12,446 | 13,712 | 12,062 | 12,374 | 14,199 | 17,112 | 19,541 |
| Borrowings | 654 | 537 | 7,178 | 7,966 | 7,143 | 8,496 | 6,305 | 5,129 | 4,158 | 4,542 | 2,922 | 5,448 | 6,217 |
| Other Liabilities | 2,550 | 3,642 | 3,957 | 4,749 | 5,300 | 5,423 | 5,968 | 4,498 | 5,340 | 5,794 | 6,539 | 6,327 | 7,651 |
| Total Liabilities | 10,135 | 13,054 | 22,298 | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,751 | 28,978 | 33,500 |
| Fixed Assets | 3,356 | 4,368 | 8,717 | 11,033 | 10,362 | 11,087 | 7,938 | 7,881 | 7,382 | 8,355 | 8,878 | 9,719 | 10,252 |
| CWIP | 304 | 576 | 2,702 | 2,133 | 2,598 | 1,640 | 940 | 1,066 | 1,146 | 1,238 | 773 | 517 | 593 |
| Investments | 178 | 1,658 | 16 | 2,136 | 262 | 2,295 | 2,374 | 2,455 | 900 | 517 | 1,075 | 1,146 | 3,331 |
| Other Assets | 6,297 | 6,451 | 10,862 | 10,910 | 12,798 | 12,639 | 13,557 | 12,028 | 12,224 | 12,690 | 13,026 | 17,596 | 19,325 |
| Total Assets | 10,135 | 13,054 | 22,298 | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,751 | 28,978 | 33,500 |
Below is a detailed analysis of the balance sheet data for Lupin Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 91.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 91.00 Cr..
- For Reserves, as of Sep 2025, the value is 19,541.00 Cr.. The value appears strong and on an upward trend. It has increased from 17,112.00 Cr. (Mar 2025) to 19,541.00 Cr., marking an increase of 2,429.00 Cr..
- For Borrowings, as of Sep 2025, the value is 6,217.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 5,448.00 Cr. (Mar 2025) to 6,217.00 Cr., marking an increase of 769.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 7,651.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,327.00 Cr. (Mar 2025) to 7,651.00 Cr., marking an increase of 1,324.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 33,500.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 28,978.00 Cr. (Mar 2025) to 33,500.00 Cr., marking an increase of 4,522.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 10,252.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,719.00 Cr. (Mar 2025) to 10,252.00 Cr., marking an increase of 533.00 Cr..
- For CWIP, as of Sep 2025, the value is 593.00 Cr.. The value appears strong and on an upward trend. It has increased from 517.00 Cr. (Mar 2025) to 593.00 Cr., marking an increase of 76.00 Cr..
- For Investments, as of Sep 2025, the value is 3,331.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,146.00 Cr. (Mar 2025) to 3,331.00 Cr., marking an increase of 2,185.00 Cr..
- For Other Assets, as of Sep 2025, the value is 19,325.00 Cr.. The value appears strong and on an upward trend. It has increased from 17,596.00 Cr. (Mar 2025) to 19,325.00 Cr., marking an increase of 1,729.00 Cr..
- For Total Assets, as of Sep 2025, the value is 33,500.00 Cr.. The value appears strong and on an upward trend. It has increased from 28,978.00 Cr. (Mar 2025) to 33,500.00 Cr., marking an increase of 4,522.00 Cr..
Notably, the Reserves (19,541.00 Cr.) exceed the Borrowings (6,217.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -651.00 | -534.00 | -4.00 | -3.00 | -4.00 | -6.00 | -4.00 | -3.00 | 215.00 | -3.00 | 1.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 80 | 76 | 116 | 91 | 120 | 128 | 129 | 108 | 95 | 98 | 86 | 88 |
| Inventory Days | 204 | 220 | 276 | 266 | 253 | 283 | 232 | 279 | 261 | 242 | 272 | 292 |
| Days Payable | 152 | 172 | 168 | 189 | 178 | 184 | 162 | 137 | 129 | 136 | 163 | 158 |
| Cash Conversion Cycle | 131 | 124 | 225 | 167 | 195 | 227 | 199 | 249 | 227 | 204 | 195 | 223 |
| Working Capital Days | 81 | 56 | 102 | 63 | 126 | 115 | 33 | 34 | 45 | 32 | 53 | 58 |
| ROCE % | 41% | 40% | 24% | 19% | 10% | 10% | 9% | 9% | -7% | 6% | 16% | 21% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Balanced Advantage Fund | 5,705,582 | 1.1 | 1188.02 | N/A | N/A | N/A |
| HDFC Large Cap Fund | 4,615,980 | 2.37 | 961.14 | N/A | N/A | N/A |
| Mirae Asset Large & Midcap Fund | 4,285,561 | 2.05 | 892.34 | N/A | N/A | N/A |
| HDFC Flexi Cap Fund | 4,200,000 | 0.93 | 874.52 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 3,083,991 | 7.59 | 642.15 | N/A | N/A | N/A |
| Mirae Asset Midcap Fund | 2,835,782 | 3.21 | 590.47 | 2,735,782 | 2025-12-15 08:40:45 | 3.66% |
| ICICI Prudential Value Fund | 2,823,402 | 0.97 | 587.89 | N/A | N/A | N/A |
| SBI ELSS Tax Saver Fund | 2,687,887 | 1.73 | 559.67 | N/A | N/A | N/A |
| Nippon India Growth Mid Cap Fund | 2,552,382 | 1.26 | 531.46 | N/A | N/A | N/A |
| Nippon India Multi Cap Fund | 2,520,027 | 1.05 | 524.72 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 71.95 | 42.05 | 9.46 | -33.65 | 26.84 |
| Diluted EPS (Rs.) | 71.95 | 41.87 | 9.41 | -33.65 | 26.72 |
| Cash EPS (Rs.) | 98.02 | 68.74 | 29.20 | 3.28 | 46.59 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 376.77 | 315.41 | 275.67 | 268.91 | 305.45 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 376.77 | 315.41 | 275.67 | 268.91 | 305.45 |
| Revenue From Operations / Share (Rs.) | 497.33 | 439.12 | 365.75 | 360.96 | 334.21 |
| PBDIT / Share (Rs.) | 120.00 | 86.26 | 41.13 | 9.44 | 59.58 |
| PBIT / Share (Rs.) | 94.39 | 59.99 | 21.78 | -27.06 | 40.02 |
| PBT / Share (Rs.) | 87.93 | 53.15 | 15.75 | -30.20 | 36.92 |
| Net Profit / Share (Rs.) | 72.41 | 42.47 | 9.84 | -33.22 | 27.04 |
| NP After MI And SOA / Share (Rs.) | 71.87 | 42.01 | 9.45 | -33.62 | 26.81 |
| PBDIT Margin (%) | 24.12 | 19.64 | 11.24 | 2.61 | 17.82 |
| PBIT Margin (%) | 18.97 | 13.66 | 5.95 | -7.49 | 11.97 |
| PBT Margin (%) | 17.68 | 12.10 | 4.30 | -8.36 | 11.04 |
| Net Profit Margin (%) | 14.55 | 9.67 | 2.69 | -9.20 | 8.08 |
| NP After MI And SOA Margin (%) | 14.45 | 9.56 | 2.58 | -9.31 | 8.02 |
| Return on Networth / Equity (%) | 19.07 | 13.39 | 3.45 | -12.57 | 8.81 |
| Return on Capital Employeed (%) | 21.29 | 17.64 | 7.23 | -9.07 | 11.96 |
| Return On Assets (%) | 11.23 | 7.97 | 1.87 | -7.00 | 5.15 |
| Long Term Debt / Equity (X) | 0.10 | 0.00 | 0.00 | 0.01 | 0.00 |
| Total Debt / Equity (X) | 0.29 | 0.18 | 0.34 | 0.31 | 0.22 |
| Asset Turnover Ratio (%) | 0.85 | 0.85 | 0.50 | 0.51 | 0.47 |
| Current Ratio (X) | 1.87 | 1.58 | 1.34 | 1.51 | 1.66 |
| Quick Ratio (X) | 1.26 | 0.99 | 0.85 | 0.94 | 1.17 |
| Inventory Turnover Ratio (X) | 4.35 | 0.87 | 0.82 | 0.77 | 0.88 |
| Dividend Payout Ratio (NP) (%) | 11.11 | 9.50 | 42.28 | -19.31 | 22.34 |
| Dividend Payout Ratio (CP) (%) | 8.19 | 5.85 | 13.87 | 225.82 | 12.92 |
| Earning Retention Ratio (%) | 88.89 | 90.50 | 57.72 | 119.31 | 77.66 |
| Cash Earning Retention Ratio (%) | 91.81 | 94.15 | 86.13 | -125.82 | 87.08 |
| Interest Coverage Ratio (X) | 18.58 | 12.61 | 6.82 | 3.00 | 19.22 |
| Interest Coverage Ratio (Post Tax) (X) | 12.21 | 7.21 | 2.63 | -9.57 | 9.72 |
| Enterprise Value (Cr.) | 94555.16 | 75275.95 | 32506.42 | 36722.71 | 47698.57 |
| EV / Net Operating Revenue (X) | 4.16 | 3.76 | 1.95 | 2.24 | 3.15 |
| EV / EBITDA (X) | 17.26 | 19.15 | 17.37 | 85.62 | 17.65 |
| MarketCap / Net Operating Revenue (X) | 4.07 | 3.68 | 1.77 | 2.07 | 3.05 |
| Retention Ratios (%) | 88.88 | 90.49 | 57.71 | 119.31 | 77.65 |
| Price / BV (X) | 5.38 | 5.16 | 2.36 | 2.79 | 3.36 |
| Price / Net Operating Revenue (X) | 4.07 | 3.68 | 1.77 | 2.07 | 3.05 |
| EarningsYield | 0.03 | 0.02 | 0.01 | -0.04 | 0.02 |
After reviewing the key financial ratios for Lupin Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 71.95. This value is within the healthy range. It has increased from 42.05 (Mar 24) to 71.95, marking an increase of 29.90.
- For Diluted EPS (Rs.), as of Mar 25, the value is 71.95. This value is within the healthy range. It has increased from 41.87 (Mar 24) to 71.95, marking an increase of 30.08.
- For Cash EPS (Rs.), as of Mar 25, the value is 98.02. This value is within the healthy range. It has increased from 68.74 (Mar 24) to 98.02, marking an increase of 29.28.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 376.77. It has increased from 315.41 (Mar 24) to 376.77, marking an increase of 61.36.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 376.77. It has increased from 315.41 (Mar 24) to 376.77, marking an increase of 61.36.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 497.33. It has increased from 439.12 (Mar 24) to 497.33, marking an increase of 58.21.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 120.00. This value is within the healthy range. It has increased from 86.26 (Mar 24) to 120.00, marking an increase of 33.74.
- For PBIT / Share (Rs.), as of Mar 25, the value is 94.39. This value is within the healthy range. It has increased from 59.99 (Mar 24) to 94.39, marking an increase of 34.40.
- For PBT / Share (Rs.), as of Mar 25, the value is 87.93. This value is within the healthy range. It has increased from 53.15 (Mar 24) to 87.93, marking an increase of 34.78.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 72.41. This value is within the healthy range. It has increased from 42.47 (Mar 24) to 72.41, marking an increase of 29.94.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 71.87. This value is within the healthy range. It has increased from 42.01 (Mar 24) to 71.87, marking an increase of 29.86.
- For PBDIT Margin (%), as of Mar 25, the value is 24.12. This value is within the healthy range. It has increased from 19.64 (Mar 24) to 24.12, marking an increase of 4.48.
- For PBIT Margin (%), as of Mar 25, the value is 18.97. This value is within the healthy range. It has increased from 13.66 (Mar 24) to 18.97, marking an increase of 5.31.
- For PBT Margin (%), as of Mar 25, the value is 17.68. This value is within the healthy range. It has increased from 12.10 (Mar 24) to 17.68, marking an increase of 5.58.
- For Net Profit Margin (%), as of Mar 25, the value is 14.55. This value exceeds the healthy maximum of 10. It has increased from 9.67 (Mar 24) to 14.55, marking an increase of 4.88.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 14.45. This value is within the healthy range. It has increased from 9.56 (Mar 24) to 14.45, marking an increase of 4.89.
- For Return on Networth / Equity (%), as of Mar 25, the value is 19.07. This value is within the healthy range. It has increased from 13.39 (Mar 24) to 19.07, marking an increase of 5.68.
- For Return on Capital Employeed (%), as of Mar 25, the value is 21.29. This value is within the healthy range. It has increased from 17.64 (Mar 24) to 21.29, marking an increase of 3.65.
- For Return On Assets (%), as of Mar 25, the value is 11.23. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 11.23, marking an increase of 3.26.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.10, marking an increase of 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from 0.18 (Mar 24) to 0.29, marking an increase of 0.11.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.85. There is no change compared to the previous period (Mar 24) which recorded 0.85.
- For Current Ratio (X), as of Mar 25, the value is 1.87. This value is within the healthy range. It has increased from 1.58 (Mar 24) to 1.87, marking an increase of 0.29.
- For Quick Ratio (X), as of Mar 25, the value is 1.26. This value is within the healthy range. It has increased from 0.99 (Mar 24) to 1.26, marking an increase of 0.27.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.35. This value is within the healthy range. It has increased from 0.87 (Mar 24) to 4.35, marking an increase of 3.48.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 11.11. This value is below the healthy minimum of 20. It has increased from 9.50 (Mar 24) to 11.11, marking an increase of 1.61.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.19. This value is below the healthy minimum of 20. It has increased from 5.85 (Mar 24) to 8.19, marking an increase of 2.34.
- For Earning Retention Ratio (%), as of Mar 25, the value is 88.89. This value exceeds the healthy maximum of 70. It has decreased from 90.50 (Mar 24) to 88.89, marking a decrease of 1.61.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.81. This value exceeds the healthy maximum of 70. It has decreased from 94.15 (Mar 24) to 91.81, marking a decrease of 2.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 18.58. This value is within the healthy range. It has increased from 12.61 (Mar 24) to 18.58, marking an increase of 5.97.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.21. This value is within the healthy range. It has increased from 7.21 (Mar 24) to 12.21, marking an increase of 5.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 94,555.16. It has increased from 75,275.95 (Mar 24) to 94,555.16, marking an increase of 19,279.21.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.16. This value exceeds the healthy maximum of 3. It has increased from 3.76 (Mar 24) to 4.16, marking an increase of 0.40.
- For EV / EBITDA (X), as of Mar 25, the value is 17.26. This value exceeds the healthy maximum of 15. It has decreased from 19.15 (Mar 24) to 17.26, marking a decrease of 1.89.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has increased from 3.68 (Mar 24) to 4.07, marking an increase of 0.39.
- For Retention Ratios (%), as of Mar 25, the value is 88.88. This value exceeds the healthy maximum of 70. It has decreased from 90.49 (Mar 24) to 88.88, marking a decrease of 1.61.
- For Price / BV (X), as of Mar 25, the value is 5.38. This value exceeds the healthy maximum of 3. It has increased from 5.16 (Mar 24) to 5.38, marking an increase of 0.22.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has increased from 3.68 (Mar 24) to 4.07, marking an increase of 0.39.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.03, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lupin Ltd:
- Net Profit Margin: 14.55%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 21.29% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 19.07% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 12.21
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.26
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 22.5 (Industry average Stock P/E: 53.08)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.29
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 14.55%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Kalpataru Inspire, 3rd Floor, Mumbai Maharashtra 400055 | info@lupin.com http://www.lupin.com |
| Management | |
|---|---|
| Name | Position Held |
| Mrs. Manju D Gupta | Chairperson |
| Mr. Nilesh D Gupta | Managing Director |
| Ms. Vinita Gupta | Director & CEO |
| Mr. Ramesh Swaminathan | Executive Director & Global CFO |
| Mr. Mark D McDade | Independent Director |
| Dr. Punita Kumar-Sinha | Independent Director |
| Mr. Jean-Luc Belingard | Independent Director |
| Mr. Jeffrey Kindler | Independent Director |
| Mr. Alfonso Zulueta | Independent Director |
| Mr. K B S Anand | Independent Director |
| Mr. Punita Lal | Independent Director |
FAQ
What is the intrinsic value of Lupin Ltd?
Lupin Ltd's intrinsic value (as of 23 December 2025) is 1603.37 which is 24.58% lower the current market price of 2,126.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 97,129 Cr. market cap, FY2025-2026 high/low of 2,403/1,774, reserves of ₹19,541 Cr, and liabilities of 33,500 Cr.
What is the Market Cap of Lupin Ltd?
The Market Cap of Lupin Ltd is 97,129 Cr..
What is the current Stock Price of Lupin Ltd as on 23 December 2025?
The current stock price of Lupin Ltd as on 23 December 2025 is 2,126.
What is the High / Low of Lupin Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lupin Ltd stocks is 2,403/1,774.
What is the Stock P/E of Lupin Ltd?
The Stock P/E of Lupin Ltd is 22.5.
What is the Book Value of Lupin Ltd?
The Book Value of Lupin Ltd is 430.
What is the Dividend Yield of Lupin Ltd?
The Dividend Yield of Lupin Ltd is 0.56 %.
What is the ROCE of Lupin Ltd?
The ROCE of Lupin Ltd is 21.3 %.
What is the ROE of Lupin Ltd?
The ROE of Lupin Ltd is 20.6 %.
What is the Face Value of Lupin Ltd?
The Face Value of Lupin Ltd is 2.00.